John Harry Cross Iii Sonnet Bio Therapeutics Holdings, Inc. (SONN) insider trading activity

John Harry Cross Iii is Chief Financial Officer of Sonnet BioTherapeutics Holdings, Inc.. Currently has a direct ownership of 1,588 shares of SONN, which is worth approximately $7,193. The most recent transaction as insider was on Dec 11, 2023, when has been sold 1,452 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.59K

0% 3M change

0% 12M change

Total Value Held $7,193

John Harry Cross III Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 11 2023	SELL Grant, award, or other acquisition	-	1,452 Reduced 47.76%	1,588 Common Stock
Feb 06 2023	SELL Payment of exercise price or tax liability	$2,077 $1.06 p/Share	1,960 Reduced 7.57%	23,927 Common Stock
Dec 14 2022	BUY Grant, award, or other acquisition	-	15,519 Added 8.81%	160,684 Common Stock
Dec 15 2021	BUY Grant, award, or other acquisition	-	66,951 Added 31.56%	145,165 Common Stock

Also insider at

SNTI

Senti Biosciences, Inc. Healthcare

Chief Financial Officer

JHC